Body Vision Medical has entered exclusive distribution agreements with Kral Medical Solutions, Paragon Care and Prism Technologies for its LungVision artificial intelligence (AI) imaging system.
The partnerships will enable Body Vision to launch the LungVision real-time, intraoperative computerised tomography (CT) imaging system in Romania, Australia and New Zealand, as well as Hong Kong, Macao and the entire Greater Bay Area (GBA).
Go deeper with GlobalData
The LungVision system has the potential to convert X-ray images captured from any C-arm device into real-time intraoperative CT scans.
Bronchoscopists can use the system to visualise pulmonary lesions in real time and ensure accurate biopsy during diagnostic bronchoscopy.
It will facilitate earlier cancer diagnosis by improving the accuracy of the lung nodule biopsy procedure through real-time image guidance.
Body Vision Medical CEO David Webster said: “We view these partnerships as a pivotal stride towards democratising Body Vision’s LungVision and giving lung patients worldwide access to the latest in AI-powered imaging technology.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“In many parts of the world with high lung cancer incidence, limited access to advanced medical solutions, has translated into lower patient survival rates. With innovative yet cost-effective solutions like LungVision, we hope to challenge and change that status quo.”
As part of its growth strategy, the company plans to expand lung patient access to LungVision in 60 new markets over the next three years.
LungVision is the company’s first commercial product, which is expected to facilitate effective treatment for lung lesions through a minimally invasive procedure.
